Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) does reduce food noise for many people who take it. Clinical trial data and real-world reports consistently show that the constant mental chatter about food (cravings, intrusive thoughts about eating, preoccupation with the next meal) diminishes significantly on semaglutide treatment. That said, it is a prescription-only medicine, and a clinician decides whether it is appropriate for you based on your individual health picture. Food noise reduction is one of the most discussed effects among people starting Wegovy, and understanding how it works, when it starts, and what it does not do will help you weigh up whether treatment is right for your situation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Food noise is the term patients and clinicians use for the relentless mental loop of eating-related thoughts: scanning for snacks, replaying yesterday's meals, planning tomorrow's, fighting the urge to eat when you are not hungry. It is not a character flaw. It reflects how the brain's reward and appetite circuits are calibrated, and those circuits have GLP-1 receptors in them.
Semaglutide is a GLP-1 receptor agonist, meaning it mimics a gut hormone that signals fullness. Crucially, GLP-1 receptors are not only in the stomach and pancreas; they are also found in the hypothalamus and other brain regions involved in reward and craving. When semaglutide activates those central receptors, it appears to dial down the salience food has in your thinking, less reward signal means food stops competing so loudly for your attention.
This is why people often describe the experience not as feeling stuffed, but as feeling indifferent: the biscuit on the counter simply stops mattering. The NHS medicines page for semaglutide explains the appetite-signalling mechanism, and it is worth reading alongside the patient information leaflet supplied with your treatment. For a deeper look at how food noise and Wegovy interact, we have covered the mechanism in detail elsewhere.
A question our prescribers hear most weeks is some version of: "How long until I stop thinking about food all the time?" There is no single answer, but the pattern is consistent enough to be useful.
Many people notice a shift during the first four weeks on the 0.25 mg starting dose, though this is often described as a gentle softening rather than a full stop. The effect tends to deepen with each dose step. By the time someone reaches the 1.7 mg or 2.4 mg maintenance dose, the reduction in food-related intrusion is usually more pronounced, though the trajectory is individual.
What matters practically is that the quieting tends to be sustained for as long as treatment continues. Large-scale semaglutide trials, including STEP 1 published in the New England Journal of Medicine, ran for 68 weeks with participants maintaining weight loss throughout, which is consistent with the appetite effects being durable rather than fading early. If you are wondering whether Wegovy actually stops food noise, the honest answer depends on dose, duration and the individual, something worth discussing with your prescriber before making any decision about duration.
If you are thinking about the practical eating side of treatment, our page on what to eat on Wegovy covers protein priorities, hydration and why the quality of what you eat matters more when appetite is suppressed.
It is worth being direct here, because the social-media version of this effect sometimes overstates it. Wegovy does not remove all interest in food, and it is not intended to. Appetite suppression and reduced food noise are features of a treatment that works alongside a reduced-calorie diet and increased physical activity, the licence is explicit on this point.
A meaningful minority of people find the effect is modest rather than dramatic, particularly at lower doses. Others find specific foods remain compelling even when general food thoughts quiet down, highly palatable, high-sugar foods can retain some pull because the dopamine pathways involved are not identical to the satiety pathway semaglutide targets most directly. You can explore the question of carbohydrates and cravings on Wegovy if that is part of your picture.
The effect also does not replace the need to pay attention to what you eat. Protein adequacy, fibre, and staying hydrated all become more important when appetite is lower, not less. Think of the reduced food noise as creating space to make better choices, it does not make those choices for you.
The decision about whether to start Wegovy sits with a clinician, and rightly so. Wegovy is a prescription-only medicine under UK law, meaning it cannot be legally supplied without a prescriber assessing your suitability. That assessment covers your BMI, any weight-related health conditions, your medication history, and contraindications, not just whether you experience food noise.
Private treatment through a regulated UK pharmacy is one route for people who do not meet NHS criteria or prefer not to wait. If cost is part of your thinking, the Wegovy pricing page sets out what is typically included in a private prescription and why a single transparent price matters for a POM.
Our clinical team at nume reviews every consultation personally, a prescriber reads your answers the same day, not a chatbot. If you want to understand the full range of treatment options available, the weight-loss treatments overview is a good starting point. When you are ready, you can speak to our prescribers through a free consultation, no referral, no waiting list, subject to clinical suitability.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.